MRK250502C75000
- 8.11
- 0.000.00%
Merck & Co Newsroom
Guggenheim Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $108
HSBC Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $100
BMO Capital Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $89
Citi Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $115
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Cuts Target Price to $99
Goldman Sachs Adjusts Merck Price Target to $99 From $103, Maintains Buy Rating
Morgan Stanley Cuts Price Target on Merck to $99 From $106, Keeps Equalweight Rating
Merck & Co. Hold Rating: Gardasil Challenges and Keytruda Exclusivity Concerns Weigh on Market Performance
BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $99
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Cuts Target Price to $97
Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $95
Research Alert: Q1 Results Beat Expectations But Tariff Related Cost Headwinds Anticipated
Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $95
AlphaValue/Baader Europe Cuts Merck KGaA Price Target on Peer Group Changes
Bernstein Remains a Hold on Merck & Company (MRK)
Cantor Fitzgerald Downgrades Merck & Co(MRK.US) to Hold Rating, Cuts Target Price to $85
Merck & Co Analyst Ratings
Goldman Sachs Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $103
A Quick Look at Today's Ratings for Merck & Co(MRK.US), With a Forecast Between $89 to $115
Merck Price Target Maintained With a $115.00/Share by Guggenheim